NCT07400952Phase 2Recruiting

Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus

Study sponsor: Glaukos Corporation

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-04Estimated
Enrollment · participants100Estimated
Source updated2026-02-10Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.